Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 31

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 31
---
 certain subjective measures, all as described in more detail under “Compensation Discussion and Analysis (CD&A).” The Compensation Committee of the Board of Directors of the Corporation does not have a policy or practice of evaluating cumulative total shareholder return as part of its determination of compensation decisions for Named Executive Officers. As noted in the “Compensation Discussion and Analysis” section of this proxy statement, the Compensation Committee reviews various compensation metrics to ensure the competitiveness of its executive compensation. The Compensation Committee determines on an annual basis the relevant objectives and goals that drive each of the Named Executive Officer’s compensation. While the Corporation’s financial condition and share price are measurements that the Corporation utilizes in evaluating the relevant objectives, the Compensation Committee also considers the advancement of the Corporation’s product candidates, both preclinical and clinical, as well as the achievement of corporative objectives, including financings, partnerships and other business development. Summary Compensation Table The following table sets out certain information respecting the compensation paid to our Chief Executive Officer, our Chief Financial Officer and Chief Medical Officer (collectively, “Named Executive Officers”)for the fiscal years ended December 31, 2024 and December 31, 2023.

| ​                            | ​ |    ​ | ​ |          ​ | ​ |         ​ | ​ |                ​ | ​ |              ​ | ​ |             ​ | ​ |         ​ |
| ​                            | ​ |    ​ | ​ |          ​ | ​ |         ​ | ​ | Restricted Share | ​ |         Option | ​ |             ​ | ​ |         ​ |
| Name and Principal Position  |   | Year |   | Salary ($) |   | Bonus ($) |   |  Unit Awards ($) |   | Awards ($) (1) | ​ | Other ($) (2) |   | Total ($) |
| Jeff Hackman, CEO            | ​ | 2024 | ​ |    225,000 | ​ |         — | ​ |                — | ​ |      1,386,862 | ​ |             — | ​ | 1,611,862 |
| ​                            | ​ | 2023 | ​ |          — | ​ |         — | ​ |                — | ​ |              — | ​ |             — | ​ |         — |
| Rostislav Raykov, former CEO |   | 2024 |   |    411,643 | ​ |   611,339 | ​ |          712,000 | ​ |        894,792 | ​ |       608